Experimental drug tested for stubborn blood disorder – but trial cut short
NCT ID NCT05676697
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested the drug Linperlisib in just 4 adults with autoimmune hemolytic anemia (AIHA) whose disease did not improve after at least two prior treatments. The goal was to see if the drug could help control the disease by targeting a key immune pathway. However, the trial was terminated early, so we have very limited information on how well it worked or its safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Linperlisib (a PI3K delta inhibitor)
- What this could lead to
- If it works, this could point toward a new treatment option for people with hard-to-treat autoimmune hemolytic anemia.
- What could go wrong
- This was a very small, early-phase trial (only 4 participants) that was terminated early, so results are limited and may not be reliable. The drug may not prove effective or safe in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE HEMOLYTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Regenerative Medicine Center
Tianjin, Tianjin Municipality, China
-
Zhoukou Central Hospital
Zhoukou, Henan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple blood test predict clot risk in antiphospholipid syndrome?
- Experimental mRNA CAR-T therapy targets autoimmune diseases in first human trial
- Engineered immune cells take on rare blood disorders
- Brain scans reveal hidden thinking problems in anemia patients
- Experimental immune therapy for stubborn anemia shows early promise but trial stalls
- Experimental CAR-T therapy takes on stubborn blood disorder